Amedica (NSDQ:AMDA) said today it closed its most recent underwritten public offering, bringing in $12.7 million to support its silicone nitride implants. The Salt Lake City, Utah-based company sold a total of 3.6 million Class A units comprised of 1 share of common stock and 1 warrant to purchase 1 share of common stock and […]
Amedica
Amedica prices $11m offering
Amedica (NSDQ:AMDA) said today that it priced a stock offering worth $11 million for the silicon nitride implants it makes. Salt Lake City, Utah-based Amedica said it plans to float more than 3.6 million shares of common stock at $1 apiece, plus nearly 7,400 preferred shares at $1,000 each, and 11 million warrants. The common stock […]
Amedica inks exclusive Chinese silicon nitride distro deal
Amedica (NSDQ:AMDA) said today it signed an exclusive distribution deal with Chinese medical device company Shandong Weigao Orthopedic Device Company Limited. The deal gives Weigao Orthopedic exclusive rights to sell, market and distribute Amedica’s silicon nitride spinal implants in the People’s Republic of China. “With more than 50,000 minimum unit sales to occur within the first […]
Amedica slumps on layoffs, restructuring plan
Amedica slashes IPO price
A day after cutting the price range on its initial public offering, medical device company Amedica wound up pricing the IPO well under even the low end of its $8-$10 range, bringing in about $20.1 million from its $5.75-per-share offering of 3.5 million shares.
Amedica lowers IPO price range, boosts shares on offer
Medical device company Amedica lowered the price range for its impending initial public offering, but said it would put more shares on offer.
Amedica looks to $35M U.S. IPO
Medical device company Amedica said it’s planning to put up nearly 3.2 million shares at $10 to $12 apiece in an initial public offering in the U.S.
Salt Lake City-based Amedica, which makes silicon nitride-based biomaterials for medical devices, said it plans to trade under the AMDA symbol on the NASDAQ exchange.
At the midpoint of the proposed offering range, Amedica would have an initial market capitalization of $143 million.
Amedica, Kyocera ink deal for silicon nitride medical devices
Amedica Corp. entered into an agreement with Kyocera Industrial Ceramics Corp. to manufacture Amedica’s silicon nitride biomaterial at Kyocera’s Vancouver, Wash., facility.
The FDA-cleared silicon nitride has the potential to promote bone growth defend against infection. Devices made from silicon nitride are semi-radiolucent with clearly visible boundaries, enabling an exact view of intra-operative placement and postoperative fusion assessment via common imaging modalities, according to a press release.
Amedica wins FDA clearance for spinal fusion device
Amedica Corp. won FDA 510(k) clearance for a 2nd generation of the company’s cervical and lumbar interbody fusion devices (IBF).
The Utah- based spinal and reconstructive medical device manufacturer said the devices, which are made with a proprietary silicon nitride biomaterial, could help surgeons perform minimally invasive procedures when conducting lumbar lateral interbody fusion (LLIF).
Amedica promotes Bryan McEntire to chief tech exec | Personnel Moves
Standard & Poor’s downgrades Medtronic | Wall Street Beat
Standard & Poor’s Ratings Services downgraded Medtronic’s (NYSE:MDT) credit rating after the company reported declines for its bread-and-butter CRM and spine businesses – which together accounted for more than 50 percent of its total Q2 revenues.
CRDM revenues were up 1.6 percent to $1.27 billion for the quarter, but defibrillator sales slid 5.0 percent to $708 million.